If you or a loved one has experienced an adverse reaction, such as blood clots, after using GLP-1 drugs, it might be beneficial to consult a lawyer
All orders include free US shipping
Current and resolved drug shortages and discontinuations reported to the FDA, Food and Drug Administration (2024) Regulatory framework for compounded preparations, National Academies Press (2020) Clinical and legal considerations in pharmaceutical compounding, The Journal of Clinical and Aesthetic Dermatology (2023) FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Medications containing semaglutide marketed for Type 2 diabetes or weight loss, Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Earlier studies have suggested that the drugs, known as GLP-1 receptor agonists, may lower dementia risk